MedTrace Logo

Profiling the Skin Microbiome in Response to Altreno in Acne Patients

NCT04548349 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2024-02-06

Study results available
· View outcomes & findings →

Summary

The study objective is to characterize the shift in the diversity and abundance of the skin microbial community at baseline and in response to Altreno monotherapy as compared to benzoyl peroxide (BPO) 2.5% leave-on gel monotherapy in acne patients.

Conditions

Interventions

DRUG

Altreno

Acne patients will be assigned to Altreno once daily.

DRUG

Benzoyl peroxide

Acne patients will be assigned to BPO leave-on gel once daily.

Sponsors & Collaborators

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-04-23
Primary Completion
2022-08-22
Completion
2022-08-22
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04548349 on ClinicalTrials.gov